מזומני החברה caratherapeutics.com (TVRD)

Steady progress in testing is supported by the diversification of logistics contracts, which creates an upward trend on the cash liquidity chart for Cara Therapeutics Inc (TVRD). The value of 0.02 represents the current metric level. The growth of reserves relies on royalties from the drug Korsuva to develop the company's own pipeline. Patent protection for the nephropathy pruritus therapy guarantees multi-year sales, establishing a reliable financial foundation for the business.
פילוחי נתונים אנליטיים מרוכזים עבור Cara Therapeutics, Inc. (TVRD)

Cara Therapeutics Inc (TVRD) is fighting for survival, restructuring its portfolio following failed clinical trials. Under these conditions, liquidity becomes a critical factor determining the operational runway without external financing. This indicator captures the actual cash balance, excluding subjective estimates and demonstrating real resilience to crises. By analyzing the company's cash on hand, an investor can assess the risk of bankruptcy or the potential for new developments.